Вутрисиран повышает выживаемость и снижает частоту сердечно-сосудистых осложнений при амилоидной кардиомиопатии транстиретина: результаты исследования HELIOS-B

Готовая научная статья объёмом 13 страниц (без учёта литературы) с приложением дополнительного материала (графики, таблицы, аналитические выкладки).

Работа выполнена в соответствии с требованиями ВАК. Структура включает все обязательные разделы:

введение, материалы и методы, результаты, обсуждение, выводы, список литературы.

Анализ основан на данных международного многоцентрового исследования и опирается на публикации, размещённые в авторитетных западных медицинских журналах 2024–2025 гг.

Подходит для публикации в профильных изданиях по кардиологии, терапии, клинической фармакологии и сердечно-сосудистой хирургии.

Может быть использована в составе ВАК-статьи, главы диссертации, отчёта по гранту или индивидуальной научной работы.

В комплекте: центральная иллюстрация, таблицы, графики, дополнительный статистический материал.

1. Maurer M.S., Bokhari S., Damy T., et al. "Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis". Circ Heart Fail . 2019;12:e006075 https://doi.org/10.1161/circheartfailure.119.006075.

CrossrefGoogle Scholar

2. Ruberg F.L., Maurer M.S. "Cardiac amyloidosis due to transthyretin protein: a review". JAMA . 2024;331:778-791. https://doi.org/10.1001/jama.2024.0442.

CrossrefMedlineGoogle Scholar

3. Nativi-Nicolau J.N., Karam C., Khella S., Maurer M.S. "Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness". Heart Fail Rev . 2022;27:785-793. https://doi.org/10.1007/s10741-021-10080-2.

CrossrefMedlineGoogle Scholar

4. Adams D., Buades J., Suhr O., Obici L., Coelho T. "Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation". Orphanet J Rare Dis . 2015;10:Suppl 1: 25.

CrossrefMedlineGoogle Scholar

5. Gentile L., Coelho T., Dispenzieri A., et al. "A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)". Orphanet J Rare Dis . 2023;18:350. https://doi.org/10.1186/s13023-023-02962-5.

CrossrefMedlineGoogle Scholar

6. Brito D., Albrecht F.C., de Arenaza D.P., et al. "World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM)". Glob Heart . 2023;18:59. https://doi.org/10.5334/gh.1262.

CrossrefMedlineGoogle Scholar

7. Garcia-Pavia P., Rapezzi C., Adler Y., et al. "Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases". Eur Heart J . 2021;42:1554-1568. https://doi.org/10.1093/eurheartj/ehab072.

CrossrefMedlineGoogle Scholar

8. Nativi-Nicolau J., Judge D.P., Hoffman J.E., et al. "Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT". ESC Heart Fail . 2021;8:3875-3884. https://doi.org/10.1002/ehf2.13541.

CrossrefMedlineGoogle Scholar

9. Pfizer. "US prescribing information: VYNDAQEL (tafamidis meglumine) capsules, for oral administration and VYNDAMAXTM (tafamidis) capsules, for oral administration". https://labeling.pfizer.com/ShowLabeling.aspx?id=11685. Accessed April 14, 2025.

Google Scholar

10. U.S. Food and Drug Administration. "Highlights of prescribing information - ATTRUBY". https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf. Accessed December 11, 2024.

Google Scholar

11. Alnylam Pharmaceuticals Inc. "US prescribing information: AMVUTTRA (vutrisiran) injection, for subcutaneous use". https://www.alnylam.com/sites/default/files/pdfs/amvuttra-us-prescribing-information.pdf. Accessed April 14, 2025.

Google Scholar

12. Habtemariam B.A., Karsten V., Attarwala H., et al. "Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering RNA conjugate, vutrisiran, in healthy subjects". Clin Pharmacol Ther . 2021;109:372-382. https://doi.org/10.1002/cpt.1974.

CrossrefMedlineGoogle Scholar

13. Adams D., Tournev I.L., Taylor M.S., et al. "Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial". Amyloid . 2023;30:1-9. https://doi.org/10.1080/13506129.2022.2091985.

CrossrefMedlineGoogle Scholar

14. Fontana M., Berk J.L., Gillmore J.D., et al. "Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy". N Engl J Med . 2025;392:33-44. https://doi.org/10.1056/NEJMoa2409134.

CrossrefMedlineGoogle Scholar

15. Gillmore J.D., Judge D.P., Cappelli F., et al. "Efficacy and safety of Acoramidis in transthyretin amyloid cardiomyopathy". N Engl J Med . 2024;390:132-142. https://doi.org/10.1056/NEJMoa2305434.

CrossrefMedlineGoogle Scholar

16. Maurer M.S., Schwartz J.H., Gundapaneni B., et al. "Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy". N Engl J Med . 2018;379:1007-1016. https://doi.org/10.1056/NEJMoa1805689.

CrossrefMedlineGoogle Scholar

17. Girard A.A., Sperry B.W. "Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis". Heart Fail Rev . 2025;30:69-73. https://doi.org/10.1007/s10741-024-10444-4.

CrossrefMedlineGoogle Scholar

18. Ioannou A., Patel R.K., Razvi Y., et al. "Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years". Circulation . 2022;146:1657-1670. https://doi.org/10.1161/CIRCULATIONAHA.122.060852.

CrossrefMedlineGoogle Scholar

19. Anker S.D., Butler J., Filippatos G., et al. "Empagliflozin in heart failure with a preserved ejection fraction". N Engl J Med . 2021;385:1451-1461. https://doi.org/10.1056/NEJMoa2107038.

CrossrefMedlineGoogle Scholar

20. Solomon S.D., McMurray J.J.V., Claggett B., et al. "Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction". N Engl J Med . 2022;387:1089-1098. https://doi.org/10.1056/NEJMoa2206286.

CrossrefMedlineGoogle Scholar

21. Solomon S.D., McMurray J.J.V., Vaduganathan M., et al. "Finerenone in heart failure with mildly reduced or preserved ejection fraction". N Engl J Med . 2024;391:1475-1485. https://doi.org/10.1056/NEJMoa2407107.

CrossrefMedlineGoogle Scholar

22. Pitt B., Zannad F., Remme W.J., et al.Randomized Aldactone Evaluation Study Investigators. "The effect of spironolactone on morbidity and mortality in patients with severe heart failure". N Engl J Med . 1999;341:709-717. https://doi.org/10.1056/nejm199909023411001.

CrossrefMedlineGoogle Scholar

23. Foа A., Vaduganathan M., Claggett B.L., et al. "Sacubitril/valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction". J Am Coll Cardiol . 2024;83:1731-1739. https://doi.org/10.1016/j.jacc.2024.02.035.

View ArticleGoogle Scholar

24. Fontana M., Berk J.L., Drachman B., et al. "Changing treatment landscape in transthyretin cardiac amyloidosis". Circ Heart Fail . 2025. e012112 https://doi.org/10.1161/circheartfailure.124.012112.

CrossrefGoogle Scholar

25. Karakasis P., Theofilis P., Patoulias D., et al. "Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis". Eur J Clin Invest . 2025. e14392 https://doi.org/10.1111/eci.14392.

CrossrefMedlineGoogle Scholar